Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269516 · ClinicalTrials.gov registry record · Phase 3
SLV308 for Treatment of Patients With Early Parkinson's Disease
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
NCT00269516: Completed Phase 3 study, sponsored by Solvay Pharmaceuticals.
NCT00269516 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 468 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00269516, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Interventions
- DRUG Placebo
- DRUG pardoprunox
- DRUG Pardoprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00269516 record still lists
NCT00269516 is an interventional study that assigns participants to a tested intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00269516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00269516 about?
NCT00269516 is a clinical study titled "SLV308 for Treatment of Patients With Early Parkinson's Disease". This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to pa...
What is the current status of trial NCT00269516?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2006-06. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00269516?
The interventions under investigation include: Placebo (DRUG), pardoprunox (DRUG), Pardoprunox (DRUG).
Who is sponsoring clinical trial NCT00269516?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00269516's enrollment target sits among peer trials
468 816th of 2000 higher than 1,185 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia